ProfileGDS5678 / 1416430_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 94% 93% 94% 95% 95% 93% 94% 96% 96% 96% 93% 95% 95% 94% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 18.2552594
GSM967853U87-EV human glioblastoma xenograft - Control 27.8209893
GSM967854U87-EV human glioblastoma xenograft - Control 38.1290894
GSM967855U87-EV human glioblastoma xenograft - Control 48.6302795
GSM967856U87-EV human glioblastoma xenograft - Control 58.5983795
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.5636193
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.9730394
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 38.6992596
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 48.798296
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 18.9109596
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.8089693
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 38.4722795
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 48.3153395
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 58.1011294